Intravenous ketamine (0.5 mg/kg) produces robust, rapid and long-lasting antidepressant effects, but is unpractical. Sublingual administration of ketamine renders better bioavailability (∼30%) and less conversion to norketamine than oral administration. We evaluated the therapeutic effects and tolerability of very low dose sublingual (VLDS) racemic ketamine (10 mg from a 100 mg/ml solution for 5 min and swallowed), repeatedly administered every 2-3 d or weekly, in 26 out-patients with refractory unipolar or bipolar depression. According to patients' reports, VLDS ketamine produced rapid, clear and sustained effects, improving mood level and stability, cognition and sleep in 20 patients (77%), with only mild and transient light-headedness as a common side-effect (no euphoria, psychotic or dissociative symptoms). Remission remained in some patients after stopping ketamine. Thus, VLDS ketamine may have broad spectrum effects beyond its antidepressant properties, with rapid onset of action, high efficacy, good tolerability and low cost, allowing extended treatment as needed.
Introduction
The rapid antidepressant effect of a single subanaesthetic i.v. dose of ketamine is one of the most significant conceptual breakthroughs in the pharmacological treatment of depression. Response to this NMDA receptor antagonist takes place within a few minutes of administration in 55-80% of subjects and may last up to 7-10 d. These robust, rapid and long-lasting effects of a single dose of i.v. ketamine (0.5 mg/kg) have been well documented in small controlled clinical trials for major depression (Berman et al., 2000; Zarate et al., 2006; Valentine et al., 2011) and bipolar depression (DiazGranados et al., 2010; Zarate et al., 2012) . Also, in selected cases the repeated i.v. administration of ketamine every 2-3 d was effective Murrough et al., 2012) , suggesting that tolerance to its antidepressant effects does not develop. One strategy aiming to maintain the acute antidepressant effect of i.v. ketamine in a feasible way was to switch to oral treatment with the glutamatergic modulator Riluzole, which was ineffective in two placebo controlled studies Ibrahim et al., 2012) .
Despite this conceptual advance, the need to submit patients to i.v. administration within a hospital setting is a strong limitation for a more widespread and continuous administration of ketamine. Thus, the application and maintenance of ketamine treatment depends on finding better routes of administration than i.v. Intramuscular injection at ∼1 mg/kg was efficacious in five case reports (Glue et al., 2011; Cusin et al., 2012; Zanicotti et al., 2012) , but is far from ideal. Ketamine after oral administration undergoes rapid first pass metabolism, resulting in only 17% bioavailability and high conversion to the metabolite norketamine (Clements et al., 1982) , but there are three case reports of successful treatment with 0.5 mg/kg oral ketamine in patients receiving hospice care (Irwin and Iglewicz, 2010; McNulty and Hahn, 2012) and two with refractory depression (Paslakis et al., 2010) . Another alternative undergoing clinical trials is the use of a nasal spray, which renders a bioavailability of 45% (Yanagihara et al., 2003) . However, ketamine in the usual liquid form is not friendly to use intranasally and may produce erratic absorption. Surprisingly, the sublingual administration of ketamine has not been explored but renders ∼30% bioavailability and less conversion to norketamine than oral administration (Yanagihara et al., 2003) . This route can be easily used with liquid ketamine and allows providing a small amount (∼1 ml) to the patient in a dropper bottle to facilitate personal use while guaranteeing that the patient does not have access to a dose that can lead to anaesthesia or psychosis. Moreover, sublingual administration of drugs has been increasingly used for psychiatric drugs and is usually well accepted by patients.
Another issue that has been poorly studied is the dose-response curve for the antidepressant effects of ketamine. Since the original description used an i.v. infusion of 0.5 mg/kg ketamine over 40 min (Berman et al., 2000) , most studies have just repeated the same protocol, but this dose selection was based on a serendipitous observation in a challenge study in depressed patients (Berman et al., 2000) . Although this is considered a subpsychotomimetic dose, perceptual disturbances, drowsiness, euphoria, feeling 'strange', confusion and dissociation often occur in this dose (DiazGranados et al., 2010; Aan Het Rot et al., 2012) . The reported efficacy of 0.5 mg/kg oral ketamine, which would lead to a bioavailability of ∼6 mg in a 70 kg subject, suggests that the habitual i.v. dose of 0.5 mg/kg (bioavailability of 30-35 mg in a 70 kg subject) is more than is actually necessary.
With these considerations in mind, we started evaluating the effects and tolerability of very low dose sublingual (VLDS) ketamine administered in outpatients with unipolar or bipolar refractory depressive episodes.
Method
This study was conducted as an unsystematic case series in a clinical setting in patients who were explained about the procedures and provided written informed consent. This form was elaborated to fulfil the requirements of the National Health Council of Brazil (Resolution 196/1996) and the Code of Ethics of the World Medical Association (Declaration of Helsinki). This was a preliminary and exploratory evaluation conducted to establish new parameters of ketamine administration (dose, route, dose interval) to carry out a systematic clinical study. Patients included in this case series had to fulfil the DSM-IV criteria for major depression (single episode or recurrent) or bipolar disorder experiencing a depressive episode. They had to have unsatisfactory response to at least four pharmacological treatments indicated for their disorder, alone or in combination, for at least 4 wk at standard therapeutic doses.
Our strategy was to start with a very low dose (0.1 ml=2 drops) of racemic ketamine 100 mg/ml (i.e. 10 mg) administered sublingually, allowed to absorb for 5 min and swallowed. We then observed for acute therapeutic effects and increased the dose by 1 drop as needed in further doses on another day. Estimating the 30% bioavailability for this route, only 3 mg ketamine would be actually delivered at this starting dose, which is about 10 times lower than ∼35 mg in a 70 kg subject undergoing the classical i.v. administration of ∼0.5 mg/kg (∼93% bioavailability) of previous studies. Then we considered the interval every 2-3 d or weekly, since its therapeutic effect tends to last for 2-7 d in most patients according to the literature and our initial observations. Maintenance of previous treatments was according to the evaluation of the psychiatrist in charge of the case, but no other medication was introduced simultaneously. Acute effects were assessed 90 min after the first ketamine dose in 11 patients with the question 'how is your mood right now?' with the possibility of giving a score from 0 to 10. Patients were instructed that 0 corresponds to being very sad/negative/anergic/distressed and 10 corresponds to being very cheerful/positive/lively/peaceful. Pre-ketamine Mood score 90 min post ketamine Fig. 1 . Acute effects of very low dose sublingual ketamine administered sublingually (10 mg for 5 min to absorb) on subjective mood state in 11 patients with a depressive episode with poor response to at least four pharmacological treatments. Mood state was rated by the patient from 0 (very sad/negative/anergic/distressed) to 10 (very cheerful/ positive/lively/peaceful) 90 min after the first ketamine dose. Figure 1 shows the acute response to VLDS ketamine in 11 of these patients with a depressive episode (five unipolar, six bipolar), with eight patients reporting a clear response after the first dose.
Results

Discussion
Our clinical observations were that VLDS ketamine produced rapid and robust effects on mood, sleep and cognition in around 75% of patients, with very good tolerability in most cases. The effect on sleep was often reported as remarkable for inducing a deep and repairing sleep, in line with previous findings of increased slow wave sleep by ketamine injection (Duncan et al., 2012) . Also, some patients retained their therapeutic response even after stopping ketamine treatment, which may be associated with the strong neuroplastic changes produced by ketamine, as shown in animal studies (Duman and Aghajanian, 2012) , but longer and more systematic observations are necessary.
These therapeutic benefits of VLDS ketamine in most patients with refractory depressive episodes resemble the descriptions of i.v. ketamine, but with better tolerance, ease of use and safety regarding psychiatric adverse events, allowing prolonged and even continuous treatment at home. Regarding clinical safety, no major complications have been reported with ketamine infusion . It is considered safe clinically as an anaesthetic and the effect of repeated treatment in patients with pain have not reported major clinical complications at higher doses than the one used here (Blonk et al., 2010; Noppers et al., 2010) . This is a preliminary exploratory study in a clinical setting with clear limitations. These include the lack of a standardized diagnostic instrument and scales to evaluate psychiatric symptoms and adverse events, the use of unsystematic dose intervals and the inclusion of both unipolar and bipolar patients, many of them with co-morbidities. Thus, the therapeutic effects were evaluated solely on the reports of patients and relatives.
These clinical observations suggest new approaches to design randomized clinical trials, preferably with an active placebo (e.g. benzodiazepine) and evaluating aspects other than depressive symptoms (e.g. mood stability, cognition). If the therapeutic effects are confirmed, VLDS ketamine may become a much more convenient strategy than moderate dose i.v. treatment, allowing its use in a wider range of patients and settings. More studies will also be needed to establish the length of treatment (short term, long term), optimal interval between doses and to better characterize its safety and tolerability.
